Read by QxMD icon Read

mack roach

Joseph Bednarek, Brianna Traxinger, Dania Brigham, Jonathan Roach, David Orlicky, Dong Wang, Roberta Pelanda, Cara L Mack
Biliary atresia (BA) is a neonatal T cell-mediated inflammatory, sclerosing cholangiopathy. In the Rhesus rotavirus (RRV)-induced neonatal mouse model of BA (murine BA), mice lacking B cells do not develop BA, and the lack of B cells is associated with loss of T cell and macrophage activation. The aim of this study was to determine the mechanism of B cell-mediated immune activation (antigen presentation versus cytokine production) in murine BA. RESULTS: Normal neonatal B cells in the liver are predominantly at pro-B and pre-B cellular development...
April 20, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
Alejandro Gonzalez-Motta, Mack Roach
PURPOSE: Stereotactic body radiation therapy (SBRT) is increasingly being used for the management of localized prostate cancer. This trend combined with declining use of brachytherapy (BT) has pushed issues and questions regarding the use of SBRT to the forefront. A systematic literature review was conducted to review the current evidence of biochemical disease-free survival (bDFS) and toxicity of SBRT in high-risk (HR) prostate cancer. METHODS AND MATERIALS: A search was carried out on the PubMed and Embase databases...
May 2018: Practical Radiation Oncology
Silke Gillessen, Gerhardt Attard, Tomasz M Beer, Himisha Beltran, Alberto Bossi, Rob Bristow, Brett Carver, Daniel Castellano, Byung Ha Chung, Noel Clarke, Gedske Daugaard, Ian D Davis, Johann de Bono, Rodolfo Borges Dos Reis, Charles G Drake, Ros Eeles, Eleni Efstathiou, Christopher P Evans, Stefano Fanti, Felix Feng, Karim Fizazi, Mark Frydenberg, Martin Gleave, Susan Halabi, Axel Heidenreich, Celestia S Higano, Nicolas James, Philip Kantoff, Pirkko-Liisa Kellokumpu-Lehtinen, Raja B Khauli, Gero Kramer, Chris Logothetis, Fernando Maluf, Alicia K Morgans, Michael J Morris, Nicolas Mottet, Vedang Murthy, William Oh, Piet Ost, Anwar R Padhani, Chris Parker, Colin C Pritchard, Mack Roach, Mark A Rubin, Charles Ryan, Fred Saad, Oliver Sartor, Howard Scher, Avishay Sella, Neal Shore, Matthew Smith, Howard Soule, Cora N Sternberg, Hiroyoshi Suzuki, Christopher Sweeney, Matthew R Sydes, Ian Tannock, Bertrand Tombal, Riccardo Valdagni, Thomas Wiegel, Aurelius Omlin
BACKGROUND: In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some of these topics. OBJECTIVE: To present the report of APCCC 2017. DESIGN, SETTING, AND PARTICIPANTS: Ten important areas of controversy in APC management were identified: high-risk localised and locally advanced prostate cancer; "oligometastatic" prostate cancer; castration-naïve and castration-resistant prostate cancer; the role of imaging in APC; osteoclast-targeted therapy; molecular characterisation of blood and tissue; genetic counselling/testing; side effects of systemic treatment(s); global access to prostate cancer drugs...
February 2018: European Urology
Colleen A F Lawton, Xiaolei Lin, Gerald E Hanks, Herbert Lepor, David J Grignon, Harmar D Brereton, Meena Bedi, Seth A Rosenthal, Kenneth L Zeitzer, Varagur M Venkatesan, Eric M Horwitz, Thomas M Pisansky, Harold Kim, Matthew B Parliament, Rachel Rabinovitch, Mack Roach, Young Kwok, James J Dignam, Howard M Sandler
PURPOSE: Trial RTOG 9202 was a phase 3 randomized trial designed to determine the optimal duration of androgen deprivation therapy (ADT) when combined with definitive radiation therapy (RT) in the treatment of locally advanced nonmetastatic adenocarcinoma of the prostate. Long-term follow-up results of this study now available are relevant to the management of this disease. METHODS AND MATERIALS: Men (N=1554) with adenocarcinoma of the prostate (cT2c-T4, N0-Nx) with a prostate-specific antigen (PSA) <150 ng/mL and no evidence of distant metastasis were randomized (June 1992 to April 1995) to short-term ADT (STAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3...
June 1, 2017: International Journal of Radiation Oncology, Biology, Physics
Li Zhang, Julian Johnson, Alexander R Gottschalk, Albert J Chang, I-Chow Hsu, Mack Roach, Zachary A Seymour
PURPOSE: The purpose of this study was to evaluate a receiver operating characteristic (ROC) curve method to determine dose thresholds with late genitourinary (GU) toxicity after stereotactic body radiation therapy for prostate cancer. METHODS AND MATERIALS: Seventy-eight patients diagnosed with low- to intermediate-risk prostate cancer and treated with stereotactic body radiation therapy alone were reviewed retrospectively. All patients received a total dose of 38 Gy in 4 fractions with a planning target volume expansion of 2 mm...
March 2017: Practical Radiation Oncology
Bryce B Reeve, David M Thissen, Carla M Bann, Nicole Mack, Katherine Treiman, Hanna K Sanoff, Nancy Roach, Brooke E Magnus, Jason He, Laura K Wagner, Rebecca Moultrie, Kathryn D Jackson, Courtney Mann, Lauren A McCormack
OBJECTIVE: To evaluate the psychometric properties of questions that assess patient perceptions of patient-provider communication and design measures of patient-centered communication (PCC). METHODS: Participants (adults with colon or rectal cancer living in North Carolina) completed a survey at 2 to 3 months post-diagnosis. The survey included 87 questions in six PCC Functions: Exchanging Information, Fostering Health Relationships, Making Decisions, Responding to Emotions, Enabling Patient Self-Management, and Managing Uncertainty...
February 10, 2017: Patient Education and Counseling
Maurice M Garcia, Alexander R Gottschalk, Jonathan Brajtbord, Badrinath R Konety, Maxwell V Meng, Mack Roach, Peter R Carroll
[This corrects the article DOI: 10.1371/journal.pone.0089754.].
2016: PloS One
Mack Roach
No abstract text is available yet for this article.
July 2016: Nature Reviews. Urology
Michael Wahl, Martina Descovich, Erin Shugard, Dilini Pinnaduwage, Atchar Sudhyadhom, Albert Chang, Mack Roach, Alexander Gottschalk, Josephine Chen
Stereotactic body radiotherapy for prostate cancer is rapidly growing in popularity. Stereotactic body radiotherapy plans mimic those of high-dose rate brachytherapy, with tight margins and inhomogeneous dose distributions. The impact of interfraction anatomical changes on the dose received by organs at risk under these conditions has not been well documented. To estimate anatomical variation during stereotactic body radiotherapy, 10 patients were identified who received a prostate boost using robotic stereotactic body radiotherapy after completing 25 fractions of pelvic radiotherapy with daily megavoltage computed tomography...
April 2017: Technology in Cancer Research & Treatment
Mack Roach
No abstract text is available yet for this article.
August 2016: Journal of Urology
Mack Roach, Reinhard Schulte, Kavita Mishra, Bruce Faddegon, Igor Barani, Ann Lazar, Eleanor A Blakely
No abstract text is available yet for this article.
2016: International Journal of Particle Therapy
Dilini S Pinnaduwage, Martina Descovich, Michael W Lometti, Badri Varad, Mack Roach, Alexander R Gottschalk
This study compares conventional and robotic intensity modulated radiation therapy (IMRT) plans for prostate boost treatments and provides clinical insight into the strengths and weaknesses of each. The potential for dose escalation with robotic IMRT is further investigated using the "critical volume tolerance" method proposed by Roach et al. Three clinically acceptable treatment plans were generated for 10 prostate boost patients: (1) a robotic IMRT plan using fixed cones, (2) a robotic IMRT plan using the Iris variable aperture collimator, and (3) a conventional linac based IMRT (c-IMRT) plan...
June 2017: Technology in Cancer Research & Treatment
Jason Chan, Mack Roach
No abstract text is available yet for this article.
March 2016: European Urology
Mekhail Anwar, Vivian Weinberg, Zachary Seymour, I Joe Hsu, Mack Roach, Alex R Gottschalk
BACKGROUND AND PURPOSE: Treatment of intermediate and high-risk prostate cancer with a high BED has been shown to increase recurrence free survival (RFS). While high dose rate (HDR) brachytherapy, given as a boost is effective in delivering a high BED, many patients are not candidates for the procedure or wish to avoid an invasive procedure. We evaluated the use of stereotactic body radiotherapy (SBRT) as a boost, with dosimetry modeled after HDR-boost. MATERIAL AND METHODS: Fifty patients were treated with two fractions of SBRT (9...
January 21, 2016: Radiation Oncology
Mack Roach, Tania L Ceron Lizarraga, Ann A Lazar
PURPOSE: The optimal treatment of clinically localized prostate cancer is controversial. Most studies focus on biochemical (PSA) failure when comparing radical prostatectomy (RP) with radiation therapy (RT), but this endpoint has not been validated as predictive of overall survival (OS) or cause-specific survival (CSS). We analyzed the available literature to determine whether reliable conclusions could be made concerning the effectiveness of RP compared with RT with or without androgen deprivation therapy (ADT), assuming current treatment standards...
December 1, 2015: International Journal of Radiation Oncology, Biology, Physics
Celia P Kaplan, Anna Maria Nápoles, Steven Narine, Steven Gregorich, Jennifer Livaudais-Toman, Tung Nguyen, Yan Leykin, Mack Roach, Eric J Small
BACKGROUND: Enrollment of minorities in clinical trials remains low. Through a California population-based study of men with early stage prostate cancer, we examined the relationships between race/ethnicity and 1) attitudes, 2) knowledge and 3) willingness to participate in clinical trials. METHODS: From November 2011-November 2012, we identified all incident cases of prostate cancer in African American, Latino, and Asian American men ages 18-75 years, and a random sample of white men diagnosed in 2008, through the California Cancer Registry, living within 60 miles of a site offering ≥ 1 clinical trial...
November 2015: Contemporary Clinical Trials
David R Raleigh, Albert J Chang, Bryan Tomlin, J Adam Cunha, Steve E Braunstein, Katsuto Shinohara, Alexander R Gottschalk, Mack Roach, I-Chow Hsu
PURPOSE: High-dose-rate (HDR) brachytherapy alone is an effective treatment option for patients with early-stage prostate cancer. The purpose of this study was to quantify patient-reported short- and long-term toxicity and quality of life (QOL) after HDR monotherapy. METHODS AND MATERIALS: Thirty-nine consecutive men between May 2001 and January 2012 were identified for this analysis. All patients underwent definitive HDR monotherapy for favorable prostate cancer to a total dose of 3150 cGy in three fractions, 3800 cGy in four fractions, or 3850 in five fractions...
November 2015: Brachytherapy
Mohamed Jalloh, Michael S Leapman, Janet E Cowan, Katsuto Shinohara, Kirsten L Greene, Mack Roach, Albert J Chang, June M Chan, Jeffry P Simko, Peter R Carroll
PURPOSE: Little is known about patterns of local failure following radiation therapy for prostate cancer. We aimed to characterize post-radiation biopsy findings, including the treatment effect and the zonal distribution of recurrent disease after radiation therapy, in men experiencing biochemical recurrence. MATERIALS AND METHODS: We identified patients who received post-radiation biopsy in the setting of biochemical recurrence following primary radiation for localized disease...
October 2015: Journal of Urology
Alberto Bossi, Thomas Wiegel, Mack Roach
No abstract text is available yet for this article.
November 2015: European Urology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"